Evidence map›Paper›PMID 42373441›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026

[Analyzing research advances in single-cell sequencing technology for immunopathological mechanisms in acute-on-chronic liver failure].

S X Zang, C J Cui, J Cui, Y L Zhang, N Fu, Y M Nan

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

S X ZangDepartment of Traditional and Western Medical Hepatology & Gastroenterology, Third Hospital of Hebei Medical University; Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Hebei Provincial International Science and Technology Cooperation Base - International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang 050051, China.
C J CuiDepartment of Traditional and Western Medical Hepatology & Gastroenterology, Third Hospital of Hebei Medical University; Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Hebei Provincial International Science and Technology Cooperation Base - International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang 050051, China.
J CuiDepartment of Traditional and Western Medical Hepatology & Gastroenterology, Third Hospital of Hebei Medical University; Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Hebei Provincial International Science and Technology Cooperation Base - International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang 050051, China.
Y L ZhangDepartment of Traditional and Western Medical Hepatology & Gastroenterology, Third Hospital of Hebei Medical University; Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Hebei Provincial International Science and Technology Cooperation Base - International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang 050051, China.
N FuDepartment of Traditional and Western Medical Hepatology & Gastroenterology, Third Hospital of Hebei Medical University; Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Hebei Provincial International Science and Technology Cooperation Base - International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang 050051, China.
Y M NanDepartment of Traditional and Western Medical Hepatology & Gastroenterology, Third Hospital of Hebei Medical University; Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Hebei Provincial International Science and Technology Cooperation Base - International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang 050051, China.

Funding

2024 Annual Artificial Liver Special Fund iGandanF-1082024-RGG0962024 Government-funded Clinical Medicine Outstanding Talent Program ZF2024072Hebei Provincial Natural Science Foundation Precision Medicine Collaborative Fund Cultivation Project H2025206096SAILING Clinical Research Project SAILING-2024008
6 · The paper itself

Abstract

Acute-on-chronic liver failure (ACLF) is a clinical syndrome characterized by acute deterioration of liver function on the basis of chronic liver disease, primarily manifested as liver and/or extrahepatic organ failure. Due to its rapid progression and poor prognosis, ACLF poses a serious threat to the patient's life. The pathogenesis process of ACLF is extremely complex, with overactivation and dysregulation of the immune system playing key roles in disease development. The high heterogeneity and complexity of immune cells have limited systematic understanding of the disease mechanisms and hindered the development of new therapies. The rise of single-cell sequencing technology has enabled the exploration of gene expression profiles at the single-cell level with high resolution, offering significant application value in analyzing the immune microenvironment and pathogenesis of ACLF, thereby helping to promote the exploration and development of new treatment methods. This review summarizes recent key advances in the application of single-cell sequencing technology in ACLF research, providing a theoretical basis for clarifying the pathogenesis and developing novel targeted treatment strategies.

Indexed as

Acute-On-Chronic Liver FailureSingle-Cell AnalysisGene Expression ProfilingHumansSingle-Cell Gene Expression Analysis

Identifiers

PMID42373441
PMCPMC13312293

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.